Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
REV3L - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
TTC39B - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
KIAA1217 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
VCPKMT - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
CYP1B1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
AFF4 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
CD200 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
ANKHD1-EIF4EBP3 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
IL17C - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
MIS18BP1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
KMT2C - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
DNM3 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
USP38 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
NPAS2 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
TFPI - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
JMJD1C - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
ADGRE5 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
MAK - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GDAP2 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
KRAS - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on